Skip to main content

Fiscal Wizard · Single-issue tearsheet

ZTS / Jun 21, 2026 Run #7546

ZTS

Zoetis Inc.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

Composite verdict

D 35.0 / 100
Bearish setup · Reversal 10 drivers · 6 gates blocking
  • Chaikin Money Flow
  • Accumulation/Distribution Line
  • Engulfing
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 25th of 85 in Drug Manufacturers - Specialty & Generic

rescore-sweep
Technical synthesisRegime: downtrend
Bull 0%Evidence: High · 21 signals100% Bear
Momentum Bearish 13Mean-reversion Neutral 43
  • Late-stage trendTrend signals have been live for 70 bars — past the ~60-bar window; momentum edge decays and can reverse late in a move. (medium confidence)
Where value comes fromMargin of safety -74%
Asset value $7.95Earnings power value $59.79Price $78.71

Priced above its no-growth earnings power value ($59.79/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Above average

68.9 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
PEGY 99
Margin of Safety 0
PEG 85
Inventory Turnover 0
Free Cash Flow Yield 85
Cash Conversion Cycle 0

Technicals Bearish

1.2 / 100

Bearish setup leads (Chaikin Money Flow, Accumulation/Distribution Line, Engulfing); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Accumulation/Distribution Line 10
Chaikin Money Flow 12
Engulfing 16

Risk Gates

6 blocking 4 caution

6 guards active, 17 signals gated.

Debt-to-Assets Blocking

High debt-to-assets blocks bullish signals — balance-sheet leverage risk.

Debt-to-Equity Blocking

High debt-to-equity blocks bullish signals — leverage risk.

LT Debt-to-Equity Blocking

High long-term D/E blocks bullish signals — structural-leverage risk.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for ZTS.